Evidence map›Paper›PMID 26371282›Full record

ReviewAnnals of oncology : official journal of the European Society for Medical Oncology2015

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

J Naidoo, D B Page, B T Li, L C Connell, K Schindler, M E Lacouture, M A Postow, J D Wolchok

Erratum issued 2 registry-linked trialsOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of oncology : official journal of the European Society for Medical Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 641 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
641citing papers in PubMed, 12 pooled it
62.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03673332 phase4terminatednot on this mapstarted 2019, after this paper: background citation

Elderly Cancer PatIents Treated for Advanced or Metastatic Melanoma or NSCLC, Safety and qualiTy of Life Under immunOtheraPies: a Phase IV Trial

TypeinterventionalSponsorInstitut Paoli-CalmettesRan2019 to 2024Enrolled40ConditionsAdvanced or Metastatic Melanoma, Advanced or Metastatic NSCLCArmsimmune-checkpoint inhibitors therapies
NCT04359199 unknown statusnot on this mapstarted 2020, after this paper: background citation

QUantitative Assessment of Swallowing After Radiation (QUASAR): A Longitudinal Comparison of Swallowing Function by Systemic Therapy in Head and Neck Cancer Patients

TypeobservationalSponsorLoren Mell, MDRan2020 to 2024Enrolled42ConditionsHead and Neck Cancer, Dysphagia, Oropharyngeal Dysphagia, Oropharynx CancerArmsRadiation Therapy, Cetuximab, Chemotherapy, Immunotherapy
3 · Its place in the literature

Who cites it

641 citing papers in PubMed, 12 syntheses or guidelines pooled it, 1,449 citations in OpenAlex.

  1. Cancer-related fatigue during treatment with neoadjuvant and/or adjuvant immune checkpoint inhibitors: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Benralizumab for Eosinophil-Related Cutaneous Adverse Events of Anticancer Therapy: A Phase II Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Article
  20. Article

581 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

J NaidooSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore jarushka_14@yahoo.com.
D B PageProvidence Portland Medical Center and Earl A. Chiles Research Institute, Portland.
B T LiDepartment of Medicine and Ludwig Center, Memorial Sloan Kettering Cancer Center, New York, USA.
L C ConnellDepartment of Medicine and Ludwig Center, Memorial Sloan Kettering Cancer Center, New York, USA.
K SchindlerDepartment of Dermatology, Medical University of Vienna, Vienna, Austria.
M E LacoutureDermatology Service, Memorial Sloan Kettering Cancer Center, New York Department of Medicine, Weill Cornell Medical College, New York, USA.
M A PostowDepartment of Medicine and Ludwig Center, Memorial Sloan Kettering Cancer Center, New York, USA Department of Medicine, Weill Cornell Medical College, New York, USA.
J D WolchokDepartment of Medicine and Ludwig Center, Memorial Sloan Kettering Cancer Center, New York, USA Department of Medicine, Weill Cornell Medical College, New York, USA.
Memorial Sloan Kettering Cancer Center · USCornell University · USJohns Hopkins University · USMedical University of Vienna · ATProvidence Portland Medical Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Immune checkpoint antibodies that augment the programmed cell death protein 1 (PD-1)/PD-L1 pathway have demonstrated antitumor activity across multiple malignancies, and gained recent regulatory approval as single-agent therapy for the treatment of metastatic malignant melanoma and nonsmall-cell lung cancer. Knowledge of toxicities associated with PD-1/PD-L1 blockade, as well as effective management algorithms for these toxicities, is pivotal in order to optimize clinical efficacy and safety. In this article, we review selected published and presented clinical studies investigating single-agent anti-PD-1/PD-L1 therapy and trials of combination approaches with other standard anticancer therapies, in multiple tumor types. We summarize the key adverse events reported in these studies and their management algorithms.

Indexed as

AnimalsAntibodies, MonoclonalB7-H1 AntigenExanthemaFatigueHumansNeoplasmsPneumoniaProgrammed Cell Death 1 ReceptorAntibodies, MonoclonalB7-H1 AntigenCD274 protein, humanProgrammed Cell Death 1 Receptoradverse eventanti-PD-1anti-PD-L1immune checkpoint antibodytoxicity

Identifiers

PMID26371282
PMCPMC6267867
OpenAlexW2177405394

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.